<DOC>
	<DOCNO>NCT00902226</DOCNO>
	<brief_summary>The purpose study evaluate effect escitalopram 12 week treatment patient Social Anxiety Disorder ( SAD ) , evaluate proportion patient respond escitalopram treatment period , evaluate safety escitalopram .</brief_summary>
	<brief_title>Escitalopram Patients With Social Anxiety Disorder</brief_title>
	<detailed_description>The study perform Russia , open-label , uncontrolled , one arm trial . The patient receive escitalopram 12 week . Start maintenance dosage well dose titration leave investigator ' decision ( 5 20 mg/day ) , accordance national Summary Products Characteristics ( SPC ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>The patient suffers SAD , diagnose accord ICD10 ( International Classification Diseases ) The patient meet criteria set national SPC escitalopram The patient , opinion investigator , otherwise healthy basis physical examination , medical history vital sign The patient has/has alcohol drug abuserelated disorder , define ICD10 The patient contraindication escitalopram The patient history severe drug allergy hypersensitivity , know hypersensitivity escitalopram The patient serious illness and/or serious sequela thereof , include liver renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , infectious , neoplastic , metabolic disturbance The patient pregnant breastfeed The patient , woman childbearing potential , use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Social Anxiety Disorder</keyword>
	<keyword>SAD</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Anxiolytic</keyword>
</DOC>